Pillstats
Rx only · Injection, Solution · Intravenous

Octreotide Acetate

Brands: Octreotide · Sandostatin · Octreotide Acetate

10 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US35 NDCs
10 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)7617
US makers10 labelers
Packages37
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 13 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$1.04$2.08$3.12$4.16May 2025Mar 2026Jul 2026
$3.425
Latest avg · Jul 22, 2026
+31%
Since May 21, 2025
10
Active US suppliers
30%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

6351.3K1.9K2.5K2025 Q12025 Q22025 Q32025 Q42026 Q1
1.9K
Rx · 2026 Q1
46K
Units dispensed
-5%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it10 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Oct 7, 2022
    RECALLRecall (Class I): Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous or Intravenous Us…

    Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe. — Recalling firm: Viatris Inc — Nationwide in the USA